Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
50 hedge funds and large institutions have $20.3M invested in Cidara Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 8 closing their positions.
10% more capital invested
Capital invested by funds: $18.4M → $20.3M (+$1.88M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 1.28% → 1.22% (-0.06%)
2% less funds holding
Funds holding: 51 → 50 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$540K |
| 2 |
WMA
West Michigan Advisors
Holland,
Michigan
|
+$96.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$60.7K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$48.8K |
| 5 |
Two Sigma Investments
New York
|
+$48.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.23M |
| 2 |
BlackRock
New York
|
-$160K |
| 3 |
Bank of New York Mellon
New York
|
-$100K |
| 4 |
VF
Virtu Financial
New York
|
-$76K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$60.2K |
CDTX Hedge Fund Activity: Q1 2024 in Review
50 of the 6,957 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2024, worth a combined $20.3M — up 10% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CDTX and 7 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $540K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.23M sold.
- 50 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2024, down from 51 in Q4 2023.
- Funds reported $20.3M of Cidara Therapeutics stock for Q1 2024, up 10% quarter-over-quarter.
- 7 funds opened new Cidara Therapeutics positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest Cidara Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $540K added.
- The largest Cidara Therapeutics seller in Q1 2024 was Nantahala Capital Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q1 2024.